What Happened?
Shares of healthcare data analytics company Health Catalyst (NASDAQ: HCAT) fell 23.1% in the afternoon session after the company provided a weak third-quarter revenue forecast and lowered its full-year outlook, despite topping second-quarter revenue expectations.
For the upcoming third quarter, Health Catalyst expects revenue of $55.5 million, a sharp sequential decline from the $70.49 million reported for the second quarter, which itself was down 12.7% year over year. The company also reduced its full-year 2026 revenue guidance to $247.5 million at the midpoint, a 5.7% decrease from its previous forecast.
This bleak outlook overshadowed the second-quarter results, in which the company's adjusted earnings per share met analysts' estimates, signaling significant challenges ahead.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Health Catalyst’s shares are extremely volatile and have had 55 moves greater than 5% over the last year. But moves this big are rare even for Health Catalyst and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 4 days ago when the stock gained 6.4% on the news that the software sector caught a massive tailwind, fueled by easing geopolitical tensions and a fresh wave of AI-driven M&A. Over the weekend, President Trump abruptly called off a planned military offensive against Iran. Yielding to pressure from Gulf allies, the administration shifted toward diplomatic talks to reopen the Strait of Hormuz. This critical de-escalation relieved pressure on global energy markets and inflation expectations, accelerating a drop in Treasury yields. For software, this shifting macro backdrop is the perfect catalyst. Lower interest rates reduce the discount rate applied to expected future cash flows, driving capital back into growth-oriented tech equities. Furthermore, a lower-yield environment provides cheaper borrowing costs to fund ongoing AI development and the aggressive acquisitions currently sweeping the industry. Strategic dealmaking continues to accelerate. Yellow.ai, a global leader in enterprise agentic AI, announced a $550 million SPAC merger with Bluerock Acquisition Corp to go public under the ticker "YAI." Meanwhile, financial automation leader AutoRek acquired Grath to integrate its AI-driven reconciliation and compliance technology.
Health Catalyst is down 24.3% since the beginning of the year, and at $1.73 per share, it is trading 53.3% below its 52-week high of $3.69 from August 2025. Investors who bought $1,000 worth of Health Catalyst’s shares 5 years ago would now be looking at only $29.92.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.
